Reflector Bio
Reflector provides a phenotypic drug discovery platform that predicts functional cellular responses to small molecules, enabling biotech and pharma teams to evaluate efficacy and off-target effects earlier than structure-based methods allow. The platform ingests any functional assay data, screens billions of compounds in silico, and delivers prioritized candidates in under four weeks. It has been used by top 20 pharma and achieved an 80% hit rate in a published validation study.
- Drug Discovery & Therapeutics
- Biotechnology
- Artificial Intelligence
- Software Only
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Prevailing drug discovery methods are structure-based, such as AlphaFold or Boltz, but they fail to account for cellular context, off-target effects, or mixed effects in vivo. When these issues surface later in development, teams are forced back to the drawing board, wasting significant time and resources. Phenotypic screening approaches that capture these effects remain resource-intensive and difficult to scale for most teams.
Solution
Reflector provides a phenotypic drug discovery platform that predicts functional cellular responses to small molecules, enabling teams to evaluate efficacy and downstream effects earlier than structure-based methods allow. The platform ingests any functional assay data to capture polypharmacology and works without a known target, making it viable for both phenotypic screening teams and target-based teams facing downstream efficacy or safety problems. Reflector screens billions of small molecules in silico, predicting functional cell response, binding affinity, and off-target effects. By optimizing for secondary and cell-based assays, the platform gives a full picture for go/no-go decisions, reducing screening volume versus traditional high-throughput screening. The entire workflow, from data input to prioritized candidates, takes under four weeks compared to a 12+ month cycle in conventional approaches.
Target Audience
Primary customers are biotech and pharmaceutical teams already screening phenotypically, as well as target-based teams encountering efficacy or safety problems downstream who need to evaluate translational outcomes earlier. The platform has been used by biotech, academic researchers, and top 20 pharma companies.
Features
- Largest phenotypic model to date, trained on 10M+ functional experiments
- Screens billions of small molecules to predict functional cell response and binding affinity
- Ingests any functional assay data, including secondary and cell-based assays, without requiring a known target
- Captures polypharmacology and mixed in vivo effects that structure-based docking methods miss
- Experimentally validated hit discovery rate with reduction in screening volume vs. traditional HTS
- Data-to-prioritized-candidates cycle of under 4 weeks versus a 12+ month conventional timeline
- Published validation study: virtual screen of 1.9 million compounds yielded 80% hit rate in vitro at 50nM potency